Treatment of hemophilic arthritis with D-penicillamine: a preliminary report.
Current medical management programs for established joint diseases in hemophiliacs are unsatisfactory and do not modify the eventual outcome. D-penicillamine, a drug effective in the proliferative synovitis of rheumatoid arthritis, was evaluated in a rabbit model of hemarthroses-induced arthritis and in four hemophiliacs with chronic synovitis. The animals had intra-articular injections of citrate (left knees) and autologous citrated whole blood (right knees). Eight weeks later, the rabbits were divided into two groups: no treatment and D-penicillamine (50 mg/kg/day, IM) until sacrificed at 6 months. The saline-injected joints showed no inflammation and no iron deposition. The blood-injected knees showed iron deposition in both groups, the D-penicillamine animals had marked suppression of chronic inflammation. Of the four patients treated, three had clinical responses (reduction in synovial thickness, reduction in number of bleeds in the affected joint). One patient, who did not respond, developed mild-moderate proteinuria. Those patients who responded received between 5.3 and 7.1 mg/kg/day of the drug. Mild abnormalities in platelet aggregation were seen in the responders. This preliminary study suggests that D-penicillamine is beneficial in the chronic synovitis/arthritis induced by hemarthroses. Further trials are recommended.
D000818:Animals; D001168:Arthritis / Q000188:drug therapy*; D006395:Hemarthrosis / Q000150:complications; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007249:Inflammation / Q000175:diagnosis; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use*; D010974:Platelet Aggregation; D011507:Proteinuria / Q000139:chemically induced; D011817:Rabbits; D013583:Synovial Membrane / Q000473:pathology; D013585:Synovitis / Q000188:drug therapy
D010396:Penicillamine